Last updated: 2026-09-07 10:17:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kyverna Therapeutics, Inc. (KYTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.25, with a market capitalization of $532.78M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.55 to $13.67. This page covers its latest market performance, valuation, price trends and company information.
$532.78M | |
$8.26 | |
$35.06 | |
$1.78 | |
$8.35 | |
439.70K | |
-- | |
-- | |
$13.67 | |
$3.55 | |
-- | |
-- |
Kyverna Therapeutics, Inc. (KYTX) last closed at $8.35 as of 2026-09-04 23:31:00, unchanged from the previous close of $8.35.
During the latest regular trading session, KYTX traded between $1.78 and $35.06, with a volume of 439.70K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Kyverna Therapeutics, Inc. (KYTX) moved from $8.33 to $8.25, representing a decline of 0.96% ($0.08).
The stock traded between $8.19 and $8.37 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 702.90 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 46.4%
KYTX is currently trading at $8.25, placing it 46.4% of the way from its 52-week low of $3.55 to its 52-week high of $13.67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 149 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kyverna Therapeutics, Inc. (KYTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.